ICCM Profile
IceCure Medical Ltd, headquartered in Caesarea, Israel, operates as a pioneering medical device company specializing in the research, development, and commercialization of innovative technologies for cryoablation, specifically for the treatment of tumors within the human body. Established in 2006, the company has focused its efforts on advancing medical solutions that harness the power of cryoablation to effectively freeze and eliminate tumors.
At the forefront of its product portfolio is the ProSense system, a state-of-the-art cryoablation solution designed specifically for the treatment of breast tumors. This cutting-edge technology provides healthcare providers with a non-invasive and minimally disruptive approach to targeting and destroying tumors, offering patients a viable alternative to traditional surgical procedures.
IceCure Medical Ltd continues to innovate within the field of cryoablation, expanding its research and development initiatives to explore new applications and potential treatments for various types of tumors and medical conditions. The company collaborates closely with medical professionals and researchers to advance clinical outcomes and enhance the efficacy of cryoablation therapies.
Committed to regulatory compliance and patient safety, IceCure Medical Ltd adheres to rigorous quality assurance standards and clinical protocols in the development and commercialization of its medical devices. The company's dedication to technological advancement and clinical excellence underscores its mission to improve patient care and outcomes in the global healthcare landscape.
|
